PLANETS
4.2.2020 03:02:07 CET | Business Wire | Press release
teamLab Planets TOKYO is a museum in Toyosu, Tokyo where you walk through water and can immerse yourself in massive artworks barefoot. In the first year since teamLab Planets TOKYO opened in July of 2018, there have been more than 1.25 million visitors from 106 countries and regions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200203005275/en/
At teamLab Planets TOKYO, two artworks in the museum will be transformed by cherry blossoms for a limited time from March 1 to April 30, 2020.
Also, with the opening of the Toyosu Fish Market and Edomae Jokamachi nearby, you can enjoy food made using fresh ingredients, collect Japanese Culture souvenirs, and enjoy local shopping.
- Cherry Blossoms Transform Two Artworks
In the work Floating in the Falling Universe of Flowers , flowers bloom and change with every passing minute, creating a universe of life that spreads across the space. For a limited time only, cherry blossoms fall in the art space.
In another artwork, Drawing on the Water Surface Created by the Dance of Koi and People - Infinity , visitors walk barefoot through real water, as koi swim across the infinite water's surface. When the koi collide with people, they bloom into cherry blossoms. The flowers that bloom change in real time according to the seasonal changes of the year.
Check the teamLab Planets website for more details: https://planets.teamlab.art/
teamLab Planets highlight video: https://youtu.be/cqiv_FV8iT4
- Become Bodily Immersed in a Massive Art Space
teamLab Planets is a museum where you walk through water. It consists of 4 vast exhibition spaces with 7 distinct artworks. The artworks are based on art collective teamLab’s concept of “Body Immersive.”
By immersing the entire body with other people in these massive “Body Immersive” artworks, the boundary between the body and the artwork dissolves, the boundaries between the self, others, and the world become something continuous, and we explore a new relationship without boundaries between ourselves and the world.
Visitors enter the museum barefoot, and become completely immersed with other visitors in the vast artwork spaces.
- Artworks Transformed by Cherry Blossoms
Floating in the Falling Universe of Flowers
teamLab, 2016-2018, Interactive Digital Installation, Endless, Sound: Hideaki Takahashi
Artwork: https://planets.teamlab.art/tokyo/ew/fitfuof/
Video: https://youtu.be/FzJ5svgIueQ
A seasonal year of flowers bloom and change with time, life spreads out into the universe.
Lie down or sit still in the space and eventually your body floats and you dissolve into the artwork world.
The artwork is rendered in real time by a computer. I is neither prerecorded nor on loop. Interaction between the viewer and the installation causes continuous change in the artwork.
Flowers grow, bud, bloom, and in time, the petals fall, and the flowers wither and die. The cycle of birth and death continues for perpetuity.
The universe at this moment in time can never be seen again.
Drawing on the Water Surface Created by the Dance of Koi and People - Infinity
teamLab, 2016-2018, Interactive Digital Installation, Endless, Sound: Hideaki Takahashi
Artwork: https://planets.teamlab.art/tokyo/ew/koi_and_people/
Video: https://youtu.be/SsRNptTOniw
Koi swim on the surface of water that stretches out into infinity. People can walk into the water.
The movement of the koi is influenced by the presence of people in the water and also other koi. When the fish collide with people they turn into flowers and scatter. Throughout a year, the flowers that bloom will change along with the seasons.
The trajectory of the koi is determined by the presence of people and these trajectories trace lines on the surface of the water.
The work is rendered in real time by a computer program. It is neither prerecorded nor on loop. The interaction between the viewer and the installation causes continuous change in the artwork. Previous visual states can never be replicated, and will never reoccur.
- Museum overview
teamLab Planets TOKYO
Address: teamLab Planets TOKYO, Toyosu 6-1-16, Koto-ku, Tokyo
Hours: Monday - Thursday 10:00 - 19:00
Friday 10:00 - 21:00
Saturday and the day before holidays 9:00 - 21:00
Sunday and Holidays 9:00 - 19:00
* Last entry 30 minutes before closing.
* Special hours Friday, March 20 - Saturday, April 4: 9:00 - 21:00
* Special hours Sunday, April 5: 9:00 - 19:00
Closed:
Thursday, February 13, 2020
Thursday, March 12, 2020
Monday, April 6, 2020
Tuesday, April 14, 2020
Wednesday, April 15,2020
Admission:
Adults (18 years and older) JPY 3,200
University students / Specialized students JPY 2,500
Junior high school students / High school students JPY 2,000
Children (Ages 4-12) JPY 800
Seniors (65 years and older) JPY 2,400
Disability discount JPY 1,600
teamLab Planets website: https://planets.teamlab.art/
teamLab Planets TOKYO Ticket Store: https://teamlabplanets.dmm.com
* Prices and opening hours are subject to change. Please check the official website before visiting.
- Social Networking Sites:
Instagram: https://www.instagram.com/teamlab.planets/
Facebook: https://www.facebook.com/TL.Planets/
Twitter: https://twitter.com/teamLabPlanets
#teamLabPlanets
- Jointly Managed Food Stand
Everything is in your hand
- Hours -
Monday - Thursday 10:00 - 18:00
Friday 10:00 - 20:00
Saturday and the day before holidays 10:00 - 20:00
Sunday and Holidays 10:00 - 18:00
- Closed -
Same as teamLab Planets
* Establishment may be closed in cases of extreme weather.
Check here for more information: https://planets.teamlab.art/tokyo/foodstand
PLANETS Co., Ltd.
The managing entity for facilities operations at teamLab Planets TOKYO and the associated restaurants.
Address: Tokyo Nihonbashi Tower 26F, 2-7-1 Nihonbashi, Chuo-ku, Tokyo
Representative: Takumi Nomoto
teamLab
teamLab (f. 2001) is an international art collective, an interdisciplinary group of various specialists such as artists, programmers, engineers, CG animators, mathematicians and architects whose collaborative practice seeks to navigate the confluence of art, science, technology, and the natural world.
teamLab aims to explore the relationship between the self and the world and new perceptions through art. In order to understand the world around them, people separate it into independent entities with perceived boundaries between them. teamLab seeks to transcend these boundaries in our perception of the world, of the relationship between the self and the world, and of the continuity of time. Everything exists in a long, fragile yet miraculous, borderless continuity of life.
teamLab has been the subject of numerous exhibitions at venues worldwide, including New York, London, Paris, Singapore, Silicon Valley, Beijing, Taipei, and Melbourne among others. The permanent museums teamLab Borderless opened in Odaiba, Tokyo in June 2018, and teamLab Borderless Shanghai in Huangpu District, Shanghai on November 5, 2019. The massive body immersive space teamLab Planets in Toyosu, Tokyo is on view until Fall 2020. The latest permanent museum teamLab SuperNature in Macao to launch in March, 2020.
teamLab’s works are in the permanent collection of the Art Gallery of New South Wales, Sydney; Art Gallery of South Australia, Adelaide; Asian Art Museum, San Francisco; Asia Society Museum, New York; Borusan Contemporary Art Collection, Istanbul; National Gallery of Victoria, Melbourne; and Amos Rex, Helsinki.
teamLab is represented by Pace Gallery .
teamLab: https://www.teamlab.art/
Instagram: https://instagram.com/teamlab/
facebook: https://www.facebook.com/teamLab.inc
twitter: https://twitter.com/teamLab_net
YouTube: https://www.youtube.com/c/teamLabART
View source version on businesswire.com: https://www.businesswire.com/news/home/20200203005275/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
